Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials
Open Access
- 31 January 2026
- journal article
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 7
Abstract
Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of the acid α-glucosidase enzyme. In LOPD treatment, enzyme replacement therapy is delivered via intravenous infusion, typically in clinical settings. Cipaglucosidase alfa is delivered with the oral enzyme stabilizer miglustat (cipa + mig). Objectives: Evaluate the safety of cipa + mig home infusions. Design: Post hoc analysis of pooled safety data from three clinical trials in adults with LOPD (NCT02675465, NCT03729362, NCT04138277). Methods: The frequency and severity of infusion-associated reactions (IARs) during cipa + mig home and clinic administration were analyzed. Results: In total, 65/151 patients (43.0%) received ⩾1 cipa + mig home treatment. Of 9185 treatments, 2024 (22.0%) were administered at home. IAR frequency was similar for home (1.3%, 26/2024) and clinic (1.8%, 129/7161). The most frequent IAR following home infusion was pyrexia (6.2% of patients). Two patients with ⩾1 home-based treatment experienced serious IARs. Conclusion: Analyses support the safety of home cipa + mig treatment in eligible adults with LOPD.Keywords
Funding Information
- Amicus Therapeutics
This publication has 16 references indexed in Scilit:
- Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective studyOrphanet Journal of Rare Diseases, 2023
- Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 PandemicHealthcare, 2023
- The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapyMolecular Genetics and Metabolism Reports, 2023
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trialThe Lancet Neurology, 2021
- Improved efficacy of a next-generation ERT in murine Pompe diseaseJCI Insight, 2019
- The humanistic burden of Pompe disease: are there still unmet needs? A systematic reviewBMC Neurology, 2017
- Consensus treatment recommendations for late‐onset Pompe diseaseMuscle & Nerve, 2011
- Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safeJournal of Inherited Metabolic Disease, 2007
- Pompe disease diagnosis and management guidelineGenetics in Medicine, 2006
- α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)Biochemical Journal, 1963